Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04469075 · ClinicalTrials.gov registry record · Phase 2
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
A Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 8
- Study locations
NCT04469075 is a Phase 2 study of Glioblastoma and Recurrent Glioblastoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT04469075, a Phase 2 study of Glioblastoma and Recurrent Glioblastoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 8
- Study locations
Study Summary
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG Clindamycin Phosphate
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities) - Hauppauge
- Memorial Sloan Kettering Cancer Center - New York
- Columbia University - New York
Illinois
- Northwestern University - Evanston
Massachusetts
- Tufts Medical Center - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Hackensack Meridian Health - Hackensack
Ohio
- University of Cincinnati Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04469075
The ClinicalTrials.gov registry entry for NCT04469075 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (56% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT04469075 reports 8 study locations spanning 6 distinct geographic areas - top geographies include New York, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04469075 about?
NCT04469075 is a clinical study titled "Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields". The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
What is the current status of trial NCT04469075?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-07-09. Estimated completion is 2026-07.
What conditions does trial NCT04469075 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Skin Toxicity.
What interventions are being tested in trial NCT04469075?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Clindamycin Phosphate (DRUG).
Who is sponsoring clinical trial NCT04469075?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04469075 being conducted?
This trial has 8 study locations across Illinois, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.